These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 22760295

  • 1. A multi-functional peptide as an HIV-1 entry inhibitor based on self-concentration, recognition, and covalent attachment.
    Zhao L, Tong P, Chen YX, Hu ZW, Wang K, Zhang YN, Zhao DS, Cai LF, Liu KL, Zhao YF, Li YM.
    Org Biomol Chem; 2012 Aug 28; 10(32):6512-20. PubMed ID: 22760295
    [Abstract] [Full Text] [Related]

  • 2. Addition of artificial salt bridge by Ile646Lys mutation in gp41 coiled-coil domain regulates 6-helical bundle formation.
    Zhao L, Hu ZW, Tong P, Chen YX, Zhao YF, Li YM.
    Bioorg Med Chem Lett; 2013 May 01; 23(9):2727-32. PubMed ID: 23522564
    [Abstract] [Full Text] [Related]

  • 3. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
    Zhu Y, Ding X, Yu D, Chong H, He Y.
    J Virol; 2019 Dec 12; 94(1):. PubMed ID: 31619552
    [Abstract] [Full Text] [Related]

  • 4. Peptide and non-peptide HIV fusion inhibitors.
    Jiang S, Zhao Q, Debnath AK.
    Curr Pharm Des; 2002 Dec 12; 8(8):563-80. PubMed ID: 11945159
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
    Pan C, Liu S, Jiang S.
    J Formos Med Assoc; 2010 Feb 12; 109(2):94-105. PubMed ID: 20206833
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA, Sackett K, Rawat SS, Shai Y, Blumenthal R.
    J Mol Biol; 2004 Jun 25; 340(1):9-14. PubMed ID: 15184018
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Differential inhibition of HIV-1 and SIV envelope-mediated cell fusion by C34 peptides derived from the C-terminal heptad repeat of gp41 from diverse strains of HIV-1, HIV-2, and SIV.
    Gustchina E, Hummer G, Bewley CA, Clore GM.
    J Med Chem; 2005 Apr 21; 48(8):3036-44. PubMed ID: 15828842
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Adding an Artificial Tail-Anchor to a Peptide-Based HIV-1 Fusion Inhibitor for Improvement of Its Potency and Resistance Profile.
    Su S, Ma Z, Hua C, Li W, Lu L, Jiang S.
    Molecules; 2017 Nov 20; 22(11):. PubMed ID: 29156603
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.